Back to News
Market Impact: 0.35
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
Source: zacks.com
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany FundamentalsAnalyst Estimates
Biogen's Q3 earnings and revenue exceeded estimates, with growth drugs driving sales. The company tightened its 2026 adjusted EPS outlook amid rising costs; the article provides no figures for the beat or outlook change.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment
BIIB0.30
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Microsoft's Big Bets on AI Start to Pay Off
- Asian shares fall as Alphabet earnings miss drags Wall St futures lower